Reply - 06/06/19
Doi : 10.1016/j.jaci.2019.03.006
Le texte complet de cet article est disponible en PDF.
| This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant nos. NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870). Additional support was provided by the National Center for Research Resources, National Institutes of Health (grant nos. RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, UL1TR000040, UL1TR001079, and 5UL1RR024992-02). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2019
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 6
P. 2334-2335 - juin 2019 Retour au numéro
Article précédent
- Sample procedure in peripheral blood mononuclear cells RNA sequencing
- Gen Lu, Jian-Hua Ren, Bo Hu, Chun-Hui He, Pei-Qiong Wu, Wen-Hui Jiang
- The many abilities of omalizumab and the unbeaten path
- Cristoforo Incorvaia, Gian G. Riario-Sforza, Erminia Ridolo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?